Report Detail
Global and China Urological Cancer Therapeutics Drugs Market Insights, Forecast to 2026
- RnM4187986 |
- 03 September, 2020 |
- Global |
- 148 Pages |
- QYResearch |
- Pharma & Healthcare
Urological Cancer Therapeutics Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Urological Cancer Therapeutics Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Urological Cancer Therapeutics Drugs market is segmented into
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Segment by Application, the Urological Cancer Therapeutics Drugs market is segmented into
Hospital
Medical Research Laboratory
Others
Regional and Country-level Analysis
The Urological Cancer Therapeutics Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Urological Cancer Therapeutics Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Urological Cancer Therapeutics Drugs Market Share Analysis
Urological Cancer Therapeutics Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Urological Cancer Therapeutics Drugs business, the date to enter into the Urological Cancer Therapeutics Drugs market, Urological Cancer Therapeutics Drugs product introduction, recent developments, etc.
The major vendors covered:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
1 Study Coverage
- 1.1 Urological Cancer Therapeutics Drugs Product Introduction
- 1.2 Market Segments
- 1.3 Key Urological Cancer Therapeutics Drugs Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
- 1.4.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type
- 1.4.2 Xofigo (radium Ra 223 dichloride)
- 1.4.3 Jevtana (cabazitaxel)
- 1.4.4 Inlyta (axitinib)
- 1.4.5 Votrient (pazopanib hydrochloride)
- 1.4.6 Sutent (sunitinib malate)
- 1.4.7 Zytiga (abiraterone acetate)
- 1.4.8 Xtandi (enzalutamide)
- 1.4.9 Opdivo (nivolumab)
- 1.4.10 Provenge (sipuleucel-T)
- 1.5 Market by Application
- 1.5.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Application
- 1.5.2 Hospital
- 1.5.3 Medical Research Laboratory
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Urological Cancer Therapeutics Drugs Market Size, Estimates and Forecasts
- 2.1.1 Global Urological Cancer Therapeutics Drugs Revenue 2015-2026
- 2.1.2 Global Urological Cancer Therapeutics Drugs Sales 2015-2026
- 2.2 Global Urological Cancer Therapeutics Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
- 2.3 Urological Cancer Therapeutics Drugs Historical Market Size by Region (2015-2020)
- 2.3.1 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
- 2.3.2 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
- 2.4 Urological Cancer Therapeutics Drugs Market Estimates and Projections by Region (2021-2026)
- 2.4.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Region (2021-2026)
- 2.4.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2021-2026)
3 Global Urological Cancer Therapeutics Drugs Competitor Landscape by Players
- 3.1 Global Top Urological Cancer Therapeutics Drugs Sales by Manufacturers
- 3.1.1 Global Urological Cancer Therapeutics Drugs Sales by Manufacturers (2015-2020)
- 3.1.2 Global Urological Cancer Therapeutics Drugs Sales Market Share by Manufacturers (2015-2020)
- 3.2 Global Urological Cancer Therapeutics Drugs Manufacturers by Revenue
- 3.2.1 Global Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2015-2020)
- 3.2.2 Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2015-2020)
- 3.2.3 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
- 3.2.4 Global Top 10 and Top 5 Companies by Urological Cancer Therapeutics Drugs Revenue in 2019
- 3.2.5 Global Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Global Urological Cancer Therapeutics Drugs Price by Manufacturers
- 3.4 Global Urological Cancer Therapeutics Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Urological Cancer Therapeutics Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Urological Cancer Therapeutics Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
- 4.1 Global Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
- 4.1.1 Global Urological Cancer Therapeutics Drugs Sales by Type (2015-2020)
- 4.1.2 Global Urological Cancer Therapeutics Drugs Revenue by Type (2015-2020)
- 4.1.3 Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Type (2015-2026)
- 4.2 Global Urological Cancer Therapeutics Drugs Market Size Forecast by Type (2021-2026)
- 4.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Type (2021-2026)
- 4.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Type (2021-2026)
- 4.2.3 Urological Cancer Therapeutics Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
- 4.3 Global Urological Cancer Therapeutics Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
- 5.1 Global Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
- 5.1.1 Global Urological Cancer Therapeutics Drugs Sales by Application (2015-2020)
- 5.1.2 Global Urological Cancer Therapeutics Drugs Revenue by Application (2015-2020)
- 5.1.3 Urological Cancer Therapeutics Drugs Price by Application (2015-2020)
- 5.2 Urological Cancer Therapeutics Drugs Market Size Forecast by Application (2021-2026)
- 5.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Application (2021-2026)
- 5.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Application (2021-2026)
- 5.2.3 Global Urological Cancer Therapeutics Drugs Price Forecast by Application (2021-2026)
6 China by Players, Type and Application
- 6.1 China Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
- 6.1.1 China Urological Cancer Therapeutics Drugs Sales YoY Growth 2015-2026
- 6.1.2 China Urological Cancer Therapeutics Drugs Revenue YoY Growth 2015-2026
- 6.1.3 China Urological Cancer Therapeutics Drugs Market Share in Global Market 2015-2026
- 6.2 China Urological Cancer Therapeutics Drugs Market Size by Players (International and Local Players)
- 6.2.1 China Top Urological Cancer Therapeutics Drugs Players by Sales (2015-2020)
- 6.2.2 China Top Urological Cancer Therapeutics Drugs Players by Revenue (2015-2020)
- 6.3 China Urological Cancer Therapeutics Drugs Historic Market Review by Type (2015-2020)
- 6.3.1 China Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
- 6.3.2 China Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2015-2020)
- 6.3.3 China Urological Cancer Therapeutics Drugs Price by Type (2015-2020)
- 6.4 China Urological Cancer Therapeutics Drugs Market Estimates and Forecasts by Type (2021-2026)
- 6.4.1 China Urological Cancer Therapeutics Drugs Sales Forecast by Type (2021-2026)
- 6.4.2 China Urological Cancer Therapeutics Drugs Revenue Forecast by Type (2021-2026)
- 6.4.3 China Urological Cancer Therapeutics Drugs Price Forecast by Type (2021-2026)
- 6.5 China Urological Cancer Therapeutics Drugs Historic Market Review by Application (2015-2020)
- 6.5.1 China Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
- 6.5.2 China Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2015-2020)
- 6.5.3 China Urological Cancer Therapeutics Drugs Price by Application (2015-2020)
- 6.6 China Urological Cancer Therapeutics Drugs Market Estimates and Forecasts by Application (2021-2026)
- 6.6.1 China Urological Cancer Therapeutics Drugs Sales Forecast by Application (2021-2026)
- 6.6.2 China Urological Cancer Therapeutics Drugs Revenue Forecast by Application (2021-2026)
- 6.6.3 China Urological Cancer Therapeutics Drugs Price Forecast by Application (2021-2026)
7 North America
- 7.1 North America Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
- 7.2 North America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
- 7.2.1 North America Urological Cancer Therapeutics Drugs Sales by Country (2015-2020)
- 7.2.2 North America Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020)
- 7.2.3 U.S.
- 7.2.4 Canada
8 Europe
- 8.1 Europe Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
- 8.2 Europe Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
- 8.2.1 Europe Urological Cancer Therapeutics Drugs Sales by Country
- 8.2.2 Europe Urological Cancer Therapeutics Drugs Revenue by Country
- 8.2.3 Germany
- 8.2.4 France
- 8.2.5 U.K.
- 8.2.6 Italy
- 8.2.7 Russia
9 Asia Pacific
- 9.1 Asia Pacific Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
- 9.2 Asia Pacific Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
- 9.2.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region (2015-2020)
- 9.2.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region
- 9.2.3 China
- 9.2.4 Japan
- 9.2.5 South Korea
- 9.2.6 India
- 9.2.7 Australia
- 9.2.8 Taiwan
- 9.2.9 Indonesia
- 9.2.10 Thailand
- 9.2.11 Malaysia
- 9.2.12 Philippines
- 9.2.13 Vietnam
10 Latin America
- 10.1 Latin America Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
- 10.2 Latin America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
- 10.2.1 Latin America Urological Cancer Therapeutics Drugs Sales by Country
- 10.2.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Country
- 10.2.3 Mexico
- 10.2.4 Brazil
- 10.2.5 Argentina
11 Middle East and Africa
- 11.1 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
- 11.2 Middle East and Africa Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
- 11.2.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country
- 11.2.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country
- 11.2.3 Turkey
- 11.2.4 Saudi Arabia
- 11.2.5 U.A.E
12 Company Profiles
- 12.1 Novartis
- 12.1.1 Novartis Corporation Information
- 12.1.2 Novartis Description and Business Overview
- 12.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
- 12.1.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
- 12.1.5 Novartis Recent Development
- 12.2 Pfizer
- 12.2.1 Pfizer Corporation Information
- 12.2.2 Pfizer Description and Business Overview
- 12.2.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
- 12.2.4 Pfizer Urological Cancer Therapeutics Drugs Products Offered
- 12.2.5 Pfizer Recent Development
- 12.3 Johnson & Johnson
- 12.3.1 Johnson & Johnson Corporation Information
- 12.3.2 Johnson & Johnson Description and Business Overview
- 12.3.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
- 12.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Products Offered
- 12.3.5 Johnson & Johnson Recent Development
- 12.4 AstraZeneca
- 12.4.1 AstraZeneca Corporation Information
- 12.4.2 AstraZeneca Description and Business Overview
- 12.4.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
- 12.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Products Offered
- 12.4.5 AstraZeneca Recent Development
- 12.5 Astellas
- 12.5.1 Astellas Corporation Information
- 12.5.2 Astellas Description and Business Overview
- 12.5.3 Astellas Sales, Revenue and Gross Margin (2015-2020)
- 12.5.4 Astellas Urological Cancer Therapeutics Drugs Products Offered
- 12.5.5 Astellas Recent Development
- 12.6 Bristol-Myers Squibb
- 12.6.1 Bristol-Myers Squibb Corporation Information
- 12.6.2 Bristol-Myers Squibb Description and Business Overview
- 12.6.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
- 12.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products Offered
- 12.6.5 Bristol-Myers Squibb Recent Development
- 12.7 Abbott Laboratories
- 12.7.1 Abbott Laboratories Corporation Information
- 12.7.2 Abbott Laboratories Description and Business Overview
- 12.7.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
- 12.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Products Offered
- 12.7.5 Abbott Laboratories Recent Development
- 12.8 Celgene Corporation
- 12.8.1 Celgene Corporation Corporation Information
- 12.8.2 Celgene Corporation Description and Business Overview
- 12.8.3 Celgene Corporation Sales, Revenue and Gross Margin (2015-2020)
- 12.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Products Offered
- 12.8.5 Celgene Corporation Recent Development
- 12.9 Dendreon Corporation
- 12.9.1 Dendreon Corporation Corporation Information
- 12.9.2 Dendreon Corporation Description and Business Overview
- 12.9.3 Dendreon Corporation Sales, Revenue and Gross Margin (2015-2020)
- 12.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Products Offered
- 12.9.5 Dendreon Corporation Recent Development
- 12.10 Ferring Pharmaceuticals
- 12.10.1 Ferring Pharmaceuticals Corporation Information
- 12.10.2 Ferring Pharmaceuticals Description and Business Overview
- 12.10.3 Ferring Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
- 12.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products Offered
- 12.10.5 Ferring Pharmaceuticals Recent Development
- 12.11 Novartis
- 12.11.1 Novartis Corporation Information
- 12.11.2 Novartis Description and Business Overview
- 12.11.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
- 12.11.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
- 12.11.5 Novartis Recent Development
- 12.12 Indevus Pharmaceuticals Inc
- 12.12.1 Indevus Pharmaceuticals Inc Corporation Information
- 12.12.2 Indevus Pharmaceuticals Inc Description and Business Overview
- 12.12.3 Indevus Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.12.4 Indevus Pharmaceuticals Inc Products Offered
- 12.12.5 Indevus Pharmaceuticals Inc Recent Development
- 12.13 Ipsen
- 12.13.1 Ipsen Corporation Information
- 12.13.2 Ipsen Description and Business Overview
- 12.13.3 Ipsen Sales, Revenue and Gross Margin (2015-2020)
- 12.13.4 Ipsen Products Offered
- 12.13.5 Ipsen Recent Development
- 12.14 Roche Healthcare
- 12.14.1 Roche Healthcare Corporation Information
- 12.14.2 Roche Healthcare Description and Business Overview
- 12.14.3 Roche Healthcare Sales, Revenue and Gross Margin (2015-2020)
- 12.14.4 Roche Healthcare Products Offered
- 12.14.5 Roche Healthcare Recent Development
- 12.15 Sanofi S.A.
- 12.15.1 Sanofi S.A. Corporation Information
- 12.15.2 Sanofi S.A. Description and Business Overview
- 12.15.3 Sanofi S.A. Sales, Revenue and Gross Margin (2015-2020)
- 12.15.4 Sanofi S.A. Products Offered
- 12.15.5 Sanofi S.A. Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Porter’s Five Forces Analysis
- 13.5 Primary Interviews with Key Urological Cancer Therapeutics Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Urological Cancer Therapeutics Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Urological Cancer Therapeutics Drugs. Industry analysis & Market Report on Urological Cancer Therapeutics Drugs is a syndicated market report, published as Global and China Urological Cancer Therapeutics Drugs Market Insights, Forecast to 2026. It is complete Research Study and Industry Analysis of Urological Cancer Therapeutics Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
